| ¿µ¹® | rejection | ÇÑ±Û | °ÅºÎ |
|---|---|---|---|
| ¼³¸í | ¾î¶² °³Ã¼ÀÇ Á¶Á÷À» ´Ù¸¥ °³Ã¼¿¡ À̽ÄÇßÀ» ¶§ ±×°ÍÀ» ¹èÁ¦ÇÏ´Â »ýü¹ÝÀÀ. °³Ã¼°£¿¡ À̽ļö¼úÀ» Çϸé óÀ½ 7~10ÀÏ Á¤µµ´Â Ç÷¾×°ø±Þµµ ȸº¹µÇ°í º°´Ù¸¥ ÀÌ»óÀ» ¹ß°ßÇÏÁö ¸øÇÏÁö¸¸, ±× ÈÄ¿¡ ±«»ç°¡ »ý±ä´Ù. ±× ¶§¹®¿¡ Àå±âÀÌ½Ä ÈÄ¿¡ °¢Á¾ Áõ»óÀÌ ¹ß»ýÇÏ¿© À̽ļö¼úÀÌ ½ÇÆÐ·Î µ¹¾Æ°¡±â ½±´Ù. »ç¶÷ÀÇ Ã¼³»¿¡ ÀÌÁ¾ÀÇ Á¶Á÷ÀÌ µé¾î°¡¸é ±×¿¡ ´ëÇØ Ç×ü°¡ ¸¸µé¾îÁø´Ù. ÀÌ´Â Ç÷¾× ¼ÓÀÇ ¸²ÇÁ±¸°¡ ±× ÀÌÁ¾Á¶Á÷¿¡ Á¢ÃËÇÏ¿© Ȱ¼ºÈµÈ »óÅ¿¡¼ ¸²ÇÁÀý·Î µÇµ¹¾Æ¿Í¼ °Å±â¼ Ç×ü¸¦ ¸¸µå´Â °ÍÀ¸·Î »ý°¢µÇ°í ÀÖ´Ù. ÀÌ Ç×ü´Â ¼¼Æ÷¼ºÇ×ü¿Í ü¾×¼ºÇ×ü·Î ³ª´©¾îÁö¸ç ÀÌ ¾çÀÚÀÇ °øµ¿ÀÛ¿ë¿¡ ÀÇÇØ °ÅºÎ¹ÝÀÀÀÌ »ý±â´Â °ÍÀ¸·Î º¸ÀδÙ. ÀÌ´Â °³Ã¼¹æÀ§¹ÝÀÀÀ̶ó°íµµ ÇÒ ¼ö ÀÖÁö¸¸ À̽ÄÁ¶Á÷ÀÇ Ç÷°üÀº ±×°ÍµéÀÇ ÀÛ¿ëÀ¸·Î ³»ÇǼ¼Æ÷°¡ »óÇÏ¿© Ç÷ÀüÀ» Çü¼ºÇϹǷΠÇ÷ÇàÀÌ µÎÀýµÈ´Ù. ±× ¶§¹®¿¡ ±«»ç°¡ »ý±â°í ±«»çÁ¶Á÷Àº ü¿Ü·Î ¹èÃâµÈ´Ù. °ÅºÎ¹ÝÀÀÀº À̽ÄÁ÷ÈÄ¿¡ »ý±â´Â °Í, ¼öÁÖ¿¡¼ ¼ö°³¿ù ÈÄ¿¡ ºñ±³Àû ±Þ¼ºÀ¸·Î »ý±â´Â °Í, ¼ö³â ÈÄ¿¡ ¼¼È÷ »ý±â´Â °ÍÀÌ ÀÖ´Ù. Àå±â À̽Ľÿ¡´Â ÀÌ ¹ÝÀÀÀ» ¾ïÁ¦Çϱâ À§ÇØ ¸é¿ª¾ïÁ¦Á¦³ª ºÎ½Å°ÑÁúÈ£¸£¸óÀ» Åõ¿©ÇÑ´Ù. |
||
| ¿µ¹® | carcinoembryonic antigen | ÇÑ±Û | ¾Ï¹è¾ÆÇ׿ø |
|---|---|---|---|
| ¼³¸í | ¿ø·¡ žÆÀÇ ÀåÁ¶Á÷¿¡¼ Á¤»óÀûÀ¸·Î Á¸ÀçÇÏ´Â ¹°Áú·Î žƱâ ÀÌÈÄ¿¡´Â Á¸ÀçÇÏÁö ¾Ê´Â ¹°ÁúÀÌ´Ù. ±×·¯³ª À§, °£, ÇãÆÄ µîÀÇ ¾ÏÀÌ ÀÖ´Â °æ¿ì¿¡ ¼ºÀο¡¼µµ Á¸ÀçÇÑ´Ù. À̸¦ ÀÌ¿ëÇØ¼ ¾ÏÀÇ Ä¡·áÈ¿°ú ÆÇÁ¤À̳ª Àç¹ß¿©ºÎÀÇ Á¶»ç¿¡ ÀÌ¿ëÇÑ´Ù. |
||
| ¿µ¹® | antigen | ÇÑ±Û | Ç׿ø |
|---|---|---|---|
| ¼³¸í | ƯÀÌÇÑ ¸é¿ª¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ¾î¶°ÇÑ ¹°Áú. ¿©±â¿¡¼ ¸»Çϴ ƯÀÌÇÑ ¸é¿ª¹ÝÀÀÀ̶õ ºñƯÀÌÀûÀÎ ¸é¿ª¹ÝÀÀ°ú´Â ¹Ý´ëµÇ´Â Àǹ̷Π±× ¹°Áú¿¡ ´ëÇØ¼ ƯÀÌÇÏ°Ô ¹ÝÀÀÇÒ ¼ö ÀÖ´Â Ç×ü³ª ±× ¹°Áú¿¡ ´ëÇØ¼ ƯÀÌÇÏ°Ô ¹ÝÀÀÇÒ ¼ö ÀÖ´Â ¼¼Æ÷¸¦ ¸¸µå´Â °ÍÀ» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | solid tumor | ÇÑ±Û | °íÇüÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷·Î ²Ë Âù Á¾¾çÀ» ¸»ÇÔ. ¹éÇ÷º´ µîÀÇ Ç÷¾×¾Ï°ú °°ÀÌ ÇüŸ¦ ÃëÇÏÁö ¾Ê°í ¾×üÀÎ »óÅÂÀÇ ¾Ï°ú ´ëÁ¶µÇ´Â ¿ë¾î·Î¼ ´Ü´ÜÇÑ µ¢¾î¸®·Î ±¸¼ºµÈ ¾Ç¼ºÁ¾¾çÀÌ´Ù. ´ëºÎºÐÀÇ Á¾¾çÀÌ ÀÌ¿¡ ÇØ´çÇÑ´Ù. ƯÈ÷ Ç¥ÇÇÁ¶Á÷¿¡¼ ±â¿øÇÑ Á¾¾çÀ» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | ulcerating tumor | ÇÑ±Û | ±Ë¾ç¼º Á¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¾¾çÀÇ Ç¥¸é¿¡ ±Ë¾çÀÌ ¹ß»ýÇÏ´Â °Í. ´ë°³, ¸Å¿ì »¡¸® ÀÚ¶ó´Â Á¾¾ç¿¡¼ Ç÷·ù °ø±ÞÀÌ Á¾¾ç¼¼Æ÷ÀÇ ÀÚ¶ó´Â ¼Óµµ¸¦ °¨´çÇÏÁö ¸øÇØ Á¾¾çÁ߽ɺΠÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁ® ±Ë¾çÀ» Çü¼ºÇÏ´Â °æ¿ì°¡ ¸¹´Ù. À°¾ÈÀ¸·Î º¸¸é »¡°²°í, ¿À̳ª¸ç, ÁöÀúºÐÇØ º¸ÀδÙ. |
||
| TARA | total articular replacement arthroplasty; tumor-associated rejection antigen |
|---|---|
| TSA | technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso... |
| TSTA | toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen... |
| LFA | left femoral artery; left frontal craniotomy; left fronto-anterior [fetal position]; leukocyte funct... |
| PA | panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'... |
| TAA | Tumor Associated Antigen |
|---|---|
| TATA | Tumor-associated transplantation antigen |
| MATSA | tumor associated surface antigen |
| T-antigen | Tumor antigen |
| AR | Acute Rejection |
self-care (ÀÚ°¡ Ä¡·á
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
|---|---|
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| hepatitis-associated antigen | A term used for the surface antigen of hepatitis B virus before its nature was established. See: hepatitis B surface antigen. (05 Mar 2000) |
| Ir associated antigen | Antigens coded for by IR (immune response) genes or antigens coded for by the genome close to the IR genes. See: Ia antigens. (18 Nov 1997) |
| tumour-associated antigen | Antigens that are highly correlated with certain tumour cells. They are not usually found, or are found to a lesser extent, on normal cells. (05 Mar 2000) |
| lymphocyte function associated antigen | A member of the integrin family that is expressed on all leukocytes and binds to ICAM-1 and ICAM-2 on a variety of cells. (05 Mar 2000) |
| lymphocyte function-associated antigen-1 | A heterodimer molecule widely expressed on cells of haematopoietic origin. Cd11a antigen comprises the alpha chain and the CD18 antigen (antigens, CD18) the beta chain. Lfa-1 is a major receptor of T-cells, B-cells, and granulocytes. It mediates the leukocyte adhesion reactions underlying cytolytic conjugate formation, helper T-cell interactions, and antibody-dependent killing by natural killer cells and granulocytes. Intracellular adhesion molecule-1 (icam-1) has been defined as a ligand for lfa-1. (12 Dec 1998) |
| accelerated rejection | A transplant rejection manifested in less than three days. (05 Mar 2000) |
| acute cellular rejection | Graft rejection which usually begins within 10 days after a graft has been transplanted into a genetically dissimilar host. Lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages which cause tissue damage. See: primary rejection. Synonym: acute rejection. (05 Mar 2000) |
| acute kidney transplant rejection | <radiology> Findings on ultrasound: globular enlargment of the kidney, swelling and hypoechogenicity of the medullary pyramids, indistinct cortico-medullary junction, foci in the renal cortex (12 Dec 1998) |
| acute rejection | Graft rejection which usually begins within 10 days after a graft has been transplanted into a genetically dissimilar host. Lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages which cause tissue damage. See: primary rejection. Synonym: acute rejection. (05 Mar 2000) |
| allograft rejection | The rejection of tissue transplanted between two genetically different individuals of the same species. Rejection is caused by T lymphocytes responding to the foreign major histocompatibility complex of the graft. Synonym: homograft. (05 Mar 2000) |
| parental rejection | Withholding of affection from or denial of attention to one's child. Child's withholding of affection from its parent. (05 Mar 2000) |
| rejection | 1. <immunology, surgery> Usually used of grafts. Any process leading to the destruction or detachment of a graft or other specified structure. 2. <psychology> Non-acceptance, negative attitudes, hostility or excessive criticism of the individual which may precipitate feelings of rejection. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|